Also, there are reports that PPARΥ (peroxisome proliferator-activated receptor gamma) antagonists, pioglitazone and rosiglitazone, which are used to treat type 2 diabetes and metabolic syndrome, equally show an increase in circulating α-Klotho in animal models [197,198]. This evidence concerns the gene KL and type 2 diabetes mellitus.